Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma
- Conditions
- Interventions
- Drug: CytarabineDrug: CyclophosphamideDrug: AsparaginaseOther: Laboratory Biomarker AnalysisDrug: Daunorubicin HydrochlorideDrug: MethotrexateDrug: MercaptopurineDrug: Leucovorin CalciumDrug: DexamethasoneDrug: PegaspargaseDrug: Doxorubicin HydrochlorideDrug: PrednisoneDrug: NelarabineDrug: Vincristine SulfateRadiation: Radiation TherapyDrug: Thioguanine
- First Posted Date
- 2006-12-05
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 1895
- Registration Number
- NCT00408005
- Locations
- 🇺🇸
Scott and White Memorial Hospital, Temple, Texas, United States
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
Treatment of Acute Lymphoblastic Leukemia in Children
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cytarabineDrug: dexamethasoneDrug: dexrazoxane hydrochlorideDrug: doxorubicin hydrochlorideDrug: leucovorin calciumDrug: etoposideDrug: mercaptopurineDrug: methotrexateDrug: methylprednisoloneDrug: pegaspargaseDrug: prednisoloneDrug: therapeutic hydrocortisoneDrug: vincristine sulfateRadiation: radiation therapy
- First Posted Date
- 2006-11-17
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 800
- Registration Number
- NCT00400946
- Locations
- 🇨🇦
McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
🇨🇦Centre de Recherche du Centre Hospitalier de l'Universite Laval, Sainte Foy, Quebec, Canada
Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- AIDS Malignancy Consortium
- Target Recruit Count
- 34
- Registration Number
- NCT00392834
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸UCLA Clinical AIDS Research and Education (CARE) Center, Los Angeles, California, United States
🇺🇸Floyd and Delores Jones Cancer Institute at Virginia Mason Medical Center, Seattle, Washington, United States
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
- Conditions
- Interventions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 107
- Registration Number
- NCT00390793
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Azacytidine With Valproic Acid Versus Ara-C in Acute Myeloid Leukemia (AML)/ Myelodysplastic Syndrome (MDS) Patients
- Conditions
- Interventions
- First Posted Date
- 2006-09-29
- Last Posted Date
- 2012-08-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT00382590
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2024-03-26
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 275
- Registration Number
- NCT00381680
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇺🇸Childrens Memorial Hospital, Chicago, Illinois, United States
Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 74
- Registration Number
- NCT00372619
- Locations
- 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸CCOP - Nevada Cancer Research Foundation, Las Vegas, Nevada, United States
🇺🇸Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2006-09-07
- Last Posted Date
- 2021-03-24
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 1070
- Registration Number
- NCT00372593
- Locations
- 🇺🇸
University of Illinois Cancer Center, Chicago, Illinois, United States
🇺🇸Childrens Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Arkansas Cancer Research Center at University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
- Conditions
- Childhood Acute Erythroleukemia (M6)Childhood Acute Megakaryocytic Leukemia (M7)Childhood Acute Minimally Differentiated Myeloid Leukemia (M0)Childhood Acute Basophilic LeukemiaChildhood Acute Myeloblastic Leukemia With Maturation (M2)Childhood Acute Eosinophilic LeukemiaChildhood Acute Monocytic Leukemia (M5b)Childhood Acute Myelomonocytic Leukemia (M4)Childhood Myelodysplastic Syndromesde Novo Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2006-08-29
- Last Posted Date
- 2022-01-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 205
- Registration Number
- NCT00369317
- Locations
- 🇺🇸
Nationwide Children's Hospital, Columbus, Ohio, United States
🇺🇸Johns Hopkins University-Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇨🇦Hospital for Sick Children, Toronto, Ontario, Canada
T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts
- Conditions
- Myelodysplastic SyndromeX-linked Lymphoproliferative Disease (XLP)Acute Myeloid LeukemiaChronic Myelogenous LeukemiaFamilial Hemophagocytic Lymphohistiocytosis (FLH)Viral-associated Hemophagocytic Syndrome (VAHS)Hemophagocytic Lymphohistiocytosis (HLH)Acute Lymphoblastic LeukemiaNon Hodgkins Lymphoma
- Interventions
- First Posted Date
- 2006-08-24
- Last Posted Date
- 2020-01-21
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 46
- Registration Number
- NCT00368355
- Locations
- 🇺🇸
Houston Methodist Hospital, Houston, Texas, United States
🇺🇸Texas Children's Hosptial, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.